Warner Chilcott plc announced that the United States Food and Drug Administration (FDA) has approved Lo Loestrin FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy. Lo Loestrin FE is a novel oral contraceptive that offers women the lowest dosage of estrogen (10 mcg) of any oral contraceptive currently available in the US market.

"We are excited about the approval of Lo Loestrin FE, which complements our women's healthcare franchise and expands the product offerings in our branded oral contraceptive portfolio," said Roger Boissonneault, president and CEO of Warner Chilcott.

Lo Loestrin FE is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.